Glanbia, an Irish nutrition company, experienced a significant surge in its shares, reaching record highs, primarily fueled by a fivefold increase in whey protein isolate prices and strong demand for high-protein products. The company's Q1 2026 performance saw group volumes tripling analyst expectations at 8.2%, leading to a 9.3% share price increase on April 29, 2026, closing at €19.15. This robust growth is largely attributed to a blossoming wellness boom and the increasing uptake of GLP-1 weight-loss medications, such as Ozempic and Wegovy, which are creating a strong demand for protein-rich foods to maintain muscle mass.
Analysts from Barclays suggest Glanbia is uniquely positioned to benefit from this shift, as GLP-1 users, while eating less, prioritize protein-rich and functional foods. Glanbia's CEO, Hugh McGuire, views GLP-1 as a "tailwind for our entire organisation," noting that protein is in strong demand from these consumers, along with energy and vitamin/mineral supplementation. The company's Optimum Nutrition, a subsidiary of Glanbia, claims its Gold Standard Whey is the world’s best-selling whey protein, contributing to Glanbia's success in meeting the growing demand in performance nutrition.
Despite the positive outlook, Glanbia faces challenges, including the rising cost of whey, a key ingredient in protein powders. McGuire previously cited a cost headwind of almost $200 million in 2025 due to unprecedented whey prices. However, the cost of whey is expected to moderate in 2026 as supply increases, which should help improve margins. The company has also implemented double-digit price increases in April, which still need to be tested by consumers and could potentially dampen volumes later in the year, as acknowledged by management. Glanbia raised its FY2026 adjusted EPS guidance to the upper end of the 7-11% growth range, with a revised midpoint of approximately 9%, exceeding prior Bloomberg consensus of 8%.
